Pantoprazol Accord (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Accord, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat gastro‑oesophageal reflux disease and related acid‑related disorders in adults.

GNH USA supplies Pantoprazol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Accord is a proton pump inhibitor that acts on the acid‑secretion pathway of the stomach. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces further erosion. - Peptic ulcer disease: supports ulcer healing by maintaining a low‑acid environment.

Pantoprazol Accord may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild, transient headache. - Diarrhoea: loose stools without blood. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Liver enzyme elevation: abnormal blood test results. - Fracture risk: reduced bone density with long‑term use.

Before initiating therapy with Pantoprazol Accord, consider the following safety measures: - Assess renal function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for reduced efficacy of drugs needing acidic pH. - Monitor long‑term use: evaluate need for continued therapy after several months. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Elderly patients: start at the lowest effective dose and monitor for adverse effects. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazol Accord can affect the plasma concentrations of several co‑administered medicines. Clinical judgement should guide monitoring and dose adjustments.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): markedly reduced absorption. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma levels. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Methotrexate (high dose): reduced renal clearance. - Digoxin: slight increase in serum concentration. - Oral contraceptives: potential decrease in efficacy.